Neonatal Murine Model of Coxsackievirus A2 Infection for the Evaluation of Antiviral Therapeutics and Vaccination.

antiviral coxsackievirus A2 foot hand mouth disease murine model vaccine

Journal

Frontiers in microbiology
ISSN: 1664-302X
Titre abrégé: Front Microbiol
Pays: Switzerland
ID NLM: 101548977

Informations de publication

Date de publication:
2021
Historique:
received: 25 01 2021
accepted: 30 04 2021
entrez: 14 6 2021
pubmed: 15 6 2021
medline: 15 6 2021
Statut: epublish

Résumé

Coxsackievirus (CV) A2 has emerged as an important etiological agent in the pathogen spectrum of hand, foot, and mouth disease (HFMD). The symptoms of CVA2 infections are generally mild, but worsen rapidly in some people, posing a serious threat to children's health. However, compared with enterovirus 71 detected frequently in fatal cases, limited attention has been paid to CVA2 infections because of its benign clinical course. In the present study, we identified three CVA2 strains from HFMD infections and used the cell-adapted CVA2 strain HN202009 to inoculate 5-day-old BALB/c mice intramuscularly. These mice developed remarkably neurological symptoms such as ataxia, hind-limb paralysis, and death. Histopathological determination showed neuronophagia, pulmonary hemorrhage, myofiberlysis and viral myocarditis. Viral replication was detected in multiple organs and tissues, and CVA2 exhibited strong tropism to muscle tissue. The severity of illness was associated with abnormally high levels of inflammatory cytokines, including interleukin (IL)-6, IL-10, tumor necrosis factor α, and monocyte chemotactic protein 1, although the blockade of these proinflammatory cytokines had no obvious protection. We also tested whether an experimental formaldehyde-inactivated CVA2 vaccine could induce protective immune response in adult mice. The CVA2 antisera from the vaccinated mice were effective against CVA2 infection. Moreover, the inactivated CVA2 vaccine could successfully generate immune protection in neonatal mice. Our results indicated that the neonatal mouse model could be a useful tool to study CVA2 infection and to develop CVA2 vaccines.

Identifiants

pubmed: 34122374
doi: 10.3389/fmicb.2021.658093
pmc: PMC8192712
doi:

Types de publication

Journal Article

Langues

eng

Pagination

658093

Informations de copyright

Copyright © 2021 Ji, Qin, Tao, Zhu, Liang, Zhou, Chen, Zhang, Yang, Duan and Jin.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

PLoS One. 2018 Sep 20;13(9):e0204359
pubmed: 30235342
Vaccine. 2019 Aug 23;37(36):5341-5349
pubmed: 31351798
Antiviral Res. 2014 May;105:26-31
pubmed: 24583030
J Virol. 2017 Jun 9;91(13):
pubmed: 28424287
Cold Spring Harb Perspect Biol. 2014 Sep 04;6(10):a016295
pubmed: 25190079
N Engl J Med. 2014 Feb 27;370(9):818-28
pubmed: 24571754
Pediatrics. 2007 Aug;120(2):e244-52
pubmed: 17671037
Curr Opin Hematol. 2018 Jan;25(1):44-51
pubmed: 28914666
J Clin Invest. 2003 Dec;112(12):1862-70
pubmed: 14679181
Virusdisease. 2017 Mar;28(1):111-114
pubmed: 28466062
Lancet. 2013 Jun 8;381(9882):2024-32
pubmed: 23726161
N Engl J Med. 2014 Feb 27;370(9):829-37
pubmed: 24571755
J Virol. 2012 Nov;86(22):11967-76
pubmed: 22951825
Vaccine. 2011 Aug 26;29(37):6269-75
pubmed: 21722686
Vaccine. 2018 Nov 12;36(46):7095-7104
pubmed: 30316529
J Med Virol. 2001 Aug;64(4):482-6
pubmed: 11468733
Sci Rep. 2016 Aug 08;6:31151
pubmed: 27499235
Intern Med. 2016;55(6):643-6
pubmed: 26984083
J Virol. 2011 Apr;85(7):3067-76
pubmed: 21228224
Microbiol Spectr. 2016 Aug;4(4):
pubmed: 27726761
Clin Sci (Lond). 2017 Jun 1;131(12):1215-1224
pubmed: 28566450
Circ Res. 2019 Sep 27;125(8):773-782
pubmed: 31476962
Proc Natl Acad Sci U S A. 2013 Sep 3;110(36):14753-8
pubmed: 23959904
Chin Med J (Engl). 2010 Jul;123(13):1679-84
pubmed: 20819628
Lancet Infect Dis. 2010 Nov;10(11):778-90
pubmed: 20961813
Clin Sci (Lond). 2012 Feb;122(4):143-59
pubmed: 22029668
J Microbiol Immunol Infect. 2017 Dec;50(6):928-930
pubmed: 28082064
J Virol. 2017 Apr 13;91(9):
pubmed: 28250116
J Gen Virol. 2003 Jul;84(Pt 7):1781-1788
pubmed: 12810872
Emerg Infect Dis. 2018 Mar;24(3):
pubmed: 29460747
J Microbiol Immunol Infect. 2010 Apr;43(2):99-104
pubmed: 20457425
Lancet Neurol. 2010 Nov;9(11):1097-105
pubmed: 20965438
Virol J. 2011 Jun 13;8:297
pubmed: 21668960
Lancet Infect Dis. 2014 Apr;14(4):308-318
pubmed: 24485991
Infect Immun. 1999 Sep;67(9):4531-8
pubmed: 10456896
Nat Rev Rheumatol. 2016 Jan;12(1):49-62
pubmed: 26656660
Nat Immunol. 2015 May;16(5):448-57
pubmed: 25898198
Hum Vaccin Immunother. 2014;10(2):360-7
pubmed: 24231751
Emerg Infect Dis. 2013 Aug;19(8):1285-8
pubmed: 23876841
Sci Rep. 2016 Dec 09;6:38874
pubmed: 27934956
J Immunol. 2001 Dec 15;167(12):6821-6
pubmed: 11739498
J Biomed Sci. 2014 Apr 17;21:31
pubmed: 24742252
Nucleic Acids Res. 2018 Jan 4;46(D1):D708-D717
pubmed: 29040670
Virol J. 2012 Sep 17;9:205
pubmed: 22985487
J Virol. 2010 Jan;84(1):661-5
pubmed: 19864378
Annu Rev Immunol. 2009;27:61-82
pubmed: 18954284
J Gen Virol. 2004 Jun;85(Pt 6):1597-1607
pubmed: 15166444
J Clin Microbiol. 2011 Jul;49(7):2426-34
pubmed: 21543560
Antiviral Res. 2016 Oct;134:50-57
pubmed: 27582066
J Clin Virol. 2016 Jan;74:37-42
pubmed: 26655266
Vaccine. 2013 Apr 26;31(18):2215-21
pubmed: 23499596
Emerg Microbes Infect. 2020 Dec;9(1):2136-2146
pubmed: 32930072
J Clin Virol. 2006 Sep;37(1):47-52
pubmed: 16861032

Auteurs

Wangquan Ji (W)

Department of Epidemiology, College of Public Health, Zhengzhou University, Zhengzhou, China.

Luwei Qin (L)

Henan Province Center for Disease Control and Prevention, Zhengzhou, China.

Ling Tao (L)

School of Public Health, Xinxiang Medical University, Xinxiang, China.

Peiyu Zhu (P)

Department of Epidemiology, College of Public Health, Zhengzhou University, Zhengzhou, China.

Ruonan Liang (R)

Department of Epidemiology, College of Public Health, Zhengzhou University, Zhengzhou, China.

Guangyuan Zhou (G)

School of Public Health, Xinxiang Medical University, Xinxiang, China.

Shuaiyin Chen (S)

Department of Epidemiology, College of Public Health, Zhengzhou University, Zhengzhou, China.

Weiguo Zhang (W)

Department of Immunology, Duke University Medical Center, Durham, NC, United States.

Haiyan Yang (H)

Department of Epidemiology, College of Public Health, Zhengzhou University, Zhengzhou, China.

Guangcai Duan (G)

Department of Epidemiology, College of Public Health, Zhengzhou University, Zhengzhou, China.

Yuefei Jin (Y)

Department of Epidemiology, College of Public Health, Zhengzhou University, Zhengzhou, China.

Classifications MeSH